血友病A AAV基因治疗后出现高滴度抑制物病例
ASC618是一种采用人/猪嵌合B域缺失FVIII转基因(ET3)的二代AAV基因治疗产品,在1/2期试验(NCT04676048)中两名患者接受输注后虽初始有因子表达,但均产生高滴度FVIII抑制物,现维持艾美赛珠单抗预防治疗;单次输注近两年后抑制物滴度虽下降但仍为高滴度,试验已中止。
要点
- 既往有>1000暴露天的经治患者仍可在AAV基因治疗后产生高滴度FVIII抑制物。
- 生物工程化转基因(ET3人/猪嵌合)可能含未诱导免疫耐受的表位。
- 未来血友病基因治疗需对生物工程化转基因进行仔细免疫原性评估。
核心结论
- ASC618基因治疗后两例患者均出现高滴度FVIII抑制物,提示生物工程化转基因需谨慎评估免疫原性。
研究设计与样本
- 1/2期试验(NCT04676048)中两名血友病A患者接受ASC618单次输注。
主要发现
- 两例患者初始有因子表达但均产生高滴度FVIII抑制物,现维持艾美赛珠单抗预防治疗。
- 单次输注近两年后抑制物滴度虽下降但仍为高滴度。
- 最可能的抑制物形成原因是ET3人/猪杂合构建体含患者未建立耐受的表位,尽管两例既往暴露天数均超过1000天。
临床怎么用
- 对既往大量FVIII暴露的经治患者,使用生物工程化转基因行基因治疗前仍需评估免疫原性风险。
局限性
- 该试验已中止,仅报告两例患者,不能推广至所有血友病A基因治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gene therapy for hemophilia A (HA) aims to provide durable hemostatic control and reduce treatment burden, but AAV-based products to date have limitations: inconsistent peak expression, declining factor levels, and immunogenicity causing transaminitis and expression loss. ASC618 (ASC Therapeutics, Milpitas, CA, USA) was developed as a second-generation gene therapy product to overcome some of these limitations, using ET3, a bioengineered chimeric human/porcine B-domain-deleted FVIII transgene, paired with a minimal liver promoter and liver codon optimization. In a phase 1/2 trial (NCT04676048), two patients received ASC618. Despite initial factor expression, both developed high-titer FVIII inhibitors and are now maintained on emicizumab prophylaxis. Although inhibitor titers have declined, both remain high-titer nearly two years after a single infusion. The best explanation for inhibitor formation is that the novel FVIII with the human-porcine hybrid construct (ET3) contained epitopes for which these patients had not developed tolerance despite both having more than 1000 exposure days to exogenous FVIII in the past. Although this trial has been halted, these cases provide important lessons for the development of future hemophilia gene therapies. They highlight the need for careful immunogenicity assessment when using bioengineered transgenes, even in previously treated patients with extensive factor VIII exposure.
引用
- Crary SE, Citla-Sridhar D, Pierce CD, et al. Cases of High-Titer Inhibitor Formation After AAV Gene Therapy for Hemophilia A. Blood. 2026. PMID: 42886677. doi:10.1182/blood.2026035372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。